An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo

Journal of Immunology

Volumn 189, Issue 5, 2012, Pages 2290-2299

  Zhang, Tong ^a   Wu, Ming Ru ^a   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H6 PROTEIN; CD28 ANTIGEN; CD3 ANTIGEN; CD3ZETA ANTIGEN; CD8ALPHA ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COCULTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL;

ANIMALS; ANTIGENS, LY; B7 ANTIGENS; CELL DEATH; GASTROINTESTINAL NEOPLASMS; HELA CELLS; HUMANS; INTERFERON-GAMMA; JURKAT CELLS; K562 CELLS; LEUKEMIA; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; STROMAL CELLS; T-LYMPHOCYTE SUBSETS; TUMOR MARKERS, BIOLOGICAL; U937 CELLS;

EID: 84865431753     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103495     Document Type: Article

References (56)

1. Rossig, C., and M. K. Brenner. 2004. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol. Ther. 10: 5-18.
2. Ho, W. Y., J. N. Blattman, M. L. Dossett, C. Yee, and P. D. Greenberg. 2003. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3: 431-437.
3. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-733.
4. Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. June. 2011. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3: 95ra73.
5. Park, T. S., S. A. Rosenberg, and R. A. Morgan. 2011. Treating cancer with genetically engineered T cells. Trends Biotechnol. 29: 550-557.
6. Sadelain, M., R. Brentjens, and I. Rivière. 2009. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21: 215-223.
7. Sadelain, M., I. Rivière, and R. Brentjens. 2003. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3: 35-45.
8. Carpenito, C., M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, et al. 2009. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106: 3360-3365.
9. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
10. Moretta, L., C. Bottino, D. Pende, R. Castriconi, M. C. Mingari, and A. Moretta. 2006. Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 18: 151-158.
11. Vivier, E., D. H. Raulet, A. Moretta, M. A. Caligiuri, L. Zitvogel, L. L. Lanier, W. M. Yokoyama, and S. Ugolini. 2011. Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
12. Correia, D. V., M. Fogli, K. Hudspeth, M. G. da Silva, D. Mavilio, and B. Silva- Santos. 2011. Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118: 992-1001.
13. Pende, D., S. Parolini, A. Pessino, S. Sivori, R. Augugliaro, L. Morelli, E. Marcenaro, L. Accame, A. Malaspina, R. Biassoni, et al. 1999. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190: 1505-1516.
14. Hollyoake, M., R. D. Campbell, and B. Aguado. 2005. NKp30 (NCR3) is a pseudogene in 12 inbred and wild mouse strains, but an expressed gene in Mus caroli. Mol. Biol. Evol. 22: 1661-1672.
15. Delahaye, N. F., S. Rusakiewicz, I. Martins, C. Ménard, S. Roux, L. Lyonnet, P. Paul, M. Sarabi, N. Chaput, M. Semeraro, et al. 2011. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17: 700-707.
16. Brandt, C. S., M. Baratin, E. C. Yi, J. Kennedy, Z. Gao, B. Fox, B. Haldeman, C. D. Ostrander, T. Kaifu, C. Chabannon, et al. 2009. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206: 1495-1503.
17. Pogge von Strandmann, E., V. R. Simhadri, B. von Tresckow, S. Sasse, K. S. Reiners, H. P. Hansen, A. Rothe, B. Böll, V. L. Simhadri, P. Borchmann, et al. 2007. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27: 965-974.
18. Sasaki, T., E. C. Gan, A. Wakeham, S. Kornbluth, T. W. Mak, and H. Okada. 2007. HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53. Genes Dev. 21: 848-861.
19. Simhadri, V. R., K. S. Reiners, H. P. Hansen, D. Topolar, V. L. Simhadri, K. Nohroudi, T. A. Kufer, A. Engert, and E. Pogge von Strandmann. 2008. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE 3: e3377.
20. Joyce, M. G., P. Tran, M. A. Zhuravleva, J. Jaw, M. Colonna, and P. D. Sun. 2011. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc. Natl. Acad. Sci. USA 108: 6223-6228.
21. Li, Y., Q. Wang, and R. A. Mariuzza. 2011. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. J. Exp. Med. 208: 703-714.
22. Zhang, T., B. A. Lemoi, and C. L. Sentman. 2005. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106: 1544-1551.
23. Zhang, T., A. Barber, and C. L. Sentman. 2006. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res. 66: 5927-5933.
24. Eriksson, M., S. K. Meadows, C. R. Wira, and C. L. Sentman. 2004. Unique phenotype of human uterine NK cells and their regulation by endogenous TGFbeta. J. Leukoc. Biol. 76: 667-675.
25. Eriksson, M., S. K. Meadows, S. Basu, T. F. Mselle, C. R. Wira, and C. L. Sentman. 2006. TLRs mediate IFN-gamma production by human uterine NK cells in endometrium. J. Immunol. 176: 6219-6224.
26. Varela-Rohena, A., C. Carpenito, E. E. Perez, M. Richardson, R. V. Parry, M. Milone, J. Scholler, X. Hao, A. Mexas, R. G. Carroll, et al. 2008. Genetic engineering of T cells for adoptive immunotherapy. Immunol. Res. 42: 166-181.
27. Moretta, L., C. Bottino, D. Pende, M. Vitale, M. C. Mingari, and A. Moretta. 2005. Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunol. Lett. 100: 7-13.
28. Vitale, M., M. Della Chiesa, S. Carlomagno, D. Pende, M. Aricò, L. Moretta, and A. Moretta. 2005. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 106: 566-571.
29. Ferlazzo, G., M. L. Tsang, L. Moretta, G. Melioli, R. M. Steinman, and C. Münz. 2002. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195: 343-351.
30. Zhang, T., A. Barber, and C. L. Sentman. 2007. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 67: 11029-11036.
31. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity 11: 263-270.
32. Zamai, L., C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale. 2007. NK cells and cancer. J. Immunol. 178: 4011-4016.
33. Kaifu, T., B. Escaliere, L. N. Gastinel, E. Vivier, and M. Baratin. 2011. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol. Life Sci. 68: 3531-3539.
34. Koh, C. Y., B. R. Blazar, T. George, L. A.Welniak, C. M. Capitini, A. Raziuddin, W. J. Murphy, and M. Bennett. 2001. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97: 3132-3137.
35. Miller, J. S., Y. Soignier, A. Panoskaltsis-Mortari, S. A. McNearney, G. H. Yun, S. K. Fautsch, D. McKenna, C. Le, T. E. Defor, L. J. Burns, et al. 2005. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051-3057.
36. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
37. Parkhurst, M. R., J. P. Riley, M. E. Dudley, and S. A. Rosenberg. 2011. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17: 6287-6297.
38. Burns, L. J., D. J.Weisdorf, T. E. DeFor, D. H. Vesole, T. L. Repka, B. R. Blazar, S. R. Burger, A. Panoskaltsis-Mortari, C. A. Keever-Taylor, M. J. Zhang, and J. S. Miller. 2003. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 32: 177-186.
39. Nguyen, P., I. Moisini, and T. L. Geiger. 2003. Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function. Blood 102: 4320-4325.
40. Emtage, P. C., A. S. Lo, E. M. Gomes, D. L. Liu, R. M. Gonzalo-Daganzo, and R. P. Junghans. 2008. Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin. Cancer Res. 14: 8112-8122.
41. Bridgeman, J. S., R. E. Hawkins, S. Bagley, M. Blaylock, M. Holland, and D. E. Gilham. 2010. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 184: 6938-6949.
42. Schroder, K., P. J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75: 163-189.
43. Blankenstein, T., and Z. Qin. 2003. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15: 148-154.
44. Wigginton, J. M., E. Gruys, L. Geiselhart, J. Subleski, K. L. Komschlies, J. W. Park, T. A. Wiltrout, K. Nagashima, T. C. Back, and R. H. Wiltrout. 2001. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J. Clin. Invest. 108: 51-62.
45. Beatty, G., and Y. Paterson. 2001. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J. Immunol. 166: 2276-2282.
46. Corthay, A., D. K. Skovseth, K. U. Lundin, E. Røsjø, H. Omholt, P. O. Hofgaard, G. Haraldsen, and B. Bogen. 2005. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22: 371-383.
47. Faroudi, M., C. Utzny, M. Salio, V. Cerundolo, M. Guiraud, S. Müller, and S. Valitutti. 2003. Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold. Proc. Natl. Acad. Sci. USA 100: 14145-14150.
48. Bloushtain, N., U. Qimron, A. Bar-Ilan, O. Hershkovitz, R. Gazit, E. Fima, M. Korc, I. Vlodavsky, N. V. Bovin, and A. Porgador. 2004. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J. Immunol. 173: 2392-2401.
49. Hershkovitz, O., M. Jarahian, A. Zilka, A. Bar-Ilan, G. Landau, S. Jivov, Y. Tekoah, R. Glicklis, J. T. Gallagher, S. C. Hoffmann, et al. 2008. Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology 18: 28-41.
50. Yin, Y., Y. Li, M. C. Kerzic, R. Martin, and R. A. Mariuzza. 2011. Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J. 30: 1137-1148.
51. Tammana, S., X. Huang, M. Wong, M. C. Milone, L. Ma, B. L. Levine, C. H. June, J. E. Wagner, B. R. Blazar, and X. Zhou. 2010. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 21: 75-86.
52. Ye, Q., M. Loisiou, B. L. Levine, M. M. Suhoski, J. L. Riley, C. H. June, G. Coukos, and D. J. Powell, Jr. 2011. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J. Transl. Med. 9: 131.
53. Boise, L. H., A. J. Minn, P. J. Noel, C. H. June, M. A. Accavitti, T. Lindsten, and C. B. Thompson. 2010. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL. Immunity. 1995. 3: 87-98.
54. J. Immunol. 185: 3788-3799.
55. Swann, J. B., and M. J. Smyth. 2007. Immune surveillance of tumors. J. Clin. Invest. 117: 1137-1146.
56. Kim, R., M. Emi, and K. Tanabe. 2007. Cancer immunoediting from immune surveillance to immune escape. Immunology 121: 1-14.